Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

NCT00867672 is registered in ClinicalTrials.gov with University Hospital Freiburg as lead sponsor.

NCT NCT00867672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00867672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy
Lead sponsor
University Hospital Freiburg
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
February 29, 2016
Enrollment
204 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia